Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

MDA trial included 1st-line patients in the EGFR cohort almost from the beginning

Here's the clintrials criteria that enables 1st-line patients to participate

Previously untreated patients are eligible only if EGFR Exon 20 mutation is confirmed using an FDA approved device: cobas® EGFR Mutation Test v2 or therascreen® EGFR RGQ PCR Kit prior to study enrollment.

Wondering if they have enough patients who were previously untreated to put together some statistics on the 24th. I would think so, after all, they provided preliminary data on the 1st 11 pts in 2nd-line last Sept so not much of a stretch that they do it for 1st-line pts if they choose to do so. What would be interesting to know is if untreated patients are able to stay on treatment longer since they should be healthier? Would love to have a glimpse of what Spectrum would expect to see in front-line from the MDA data. IMO, MDAs 1st-line data helped grease the wheels with the FDA in getting the front-line trials going.